Skip to main content
. 2020 Sep 10;8(2):e000860. doi: 10.1136/jitc-2020-000860

Figure 3.

Figure 3

In vivo antitumor activity of CD25-ADC in the s.c. CT26 syngeneic model. Treatment with (i) vehicle, (ii) anti-PD-1 antibody (5 mg/kg, on days 2, 5, and 8), (iii) isotype-ADC (1 mg/kg, single dose on day 1) alone or (iv) in combination with anti-PD-1 antibody, (v–vii) CD25-ADC (0.1, 0.5, and 1 mg/kg single dose on day 1) alone or (viii–x) in combination with anti-PD-1 antibody, started at a group mean tumor volume of 110 mm3. Data are shown as tumor volumes (mm3) over time for each individual mouse (10 mice/group). (xi) Survival of mice shown in i–x.